Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, unique proteins that regulate vital biological functions that are impaired in various disease states. Targacept’s clinical pipeline includes multiple Phase 2 product candidates, all representing first-in-class opportunities. Targacept leverages its scientific leadership and diverse pipeline to attract significant collaborations with global pharmaceutical companies. For more information, please visit www.targacept.com.
| Website | http://www.targacept.com |
| Revenue | $17.6 million |
| Employees | 31 (13 on RocketReach) |
| Founded | 1997 |
| Address | 100 North Main Street Suite 1510, Winston-Salem, North Carolina 27101, US |
| Technologies |
JavaScript
,
HTML
,
PHP
+39 more
(view full list)
|
| Industry | Biotechnology Research |
| Web Rank | 5 Million |
| Keywords | Neurology, Nervous System, Biotechnology, Drug Development, Neuroscience, Central Nervous System, Pharmaceutical Research, Biopharmaceutical, Therapeutics, Drug Discovery, Innovative Treatments, Clinical Trials, Disorders, Pipeline |
| Competitors | Neurocrine Biosciences, Aptinyx Inc., Sage Therapeutics, Zynerba Pharmaceuticals, Syndax Pharmaceuticals, Omeros Corporation, PhaseBio Pharmaceuticals, Inc., Acorda Therapeutics, Inc., Avanir Pharmaceuticals, Anavex Life Sciences +54 more (view full list) |
Looking for a particular Targacept, Inc. employee's phone or email?
The Targacept, Inc. annual revenue was $17.6 million in 2026.
Hodges Mauri is the VP of Finance and Administration and Interim Chief Financial Officer of Targacept, Inc..
13 people are employed at Targacept, Inc..
Targacept, Inc. is based in Winston-Salem, North Carolina.